These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 8298199

  • 21. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [Abstract] [Full Text] [Related]

  • 22. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.
    Bone HG, Downs RW, Tucci JR, Harris ST, Weinstein RS, Licata AA, McClung MR, Kimmel DB, Gertz BJ, Hale E, Polvino WJ.
    J Clin Endocrinol Metab; 1997 Jan; 82(1):265-74. PubMed ID: 8989272
    [Abstract] [Full Text] [Related]

  • 23. An open-label extension study of alendronate treatment in elderly women with osteoporosis.
    Downs RW, Bone HG, McIlwain H, Baker MZ, Yates AJ, Lombardi A, Krupa D, Harning R.
    Calcif Tissue Int; 1999 Jun; 64(6):463-9. PubMed ID: 10341016
    [Abstract] [Full Text] [Related]

  • 24. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.
    Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ.
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2129-34. PubMed ID: 10852440
    [Abstract] [Full Text] [Related]

  • 25. Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass.
    Felsenberg D, Bock O, Börst H, Armbrecht G, Beller G, Degner C, Stephan-Oelkers M, Schacht E, Mazor Z, Hashimoto J, Roth HJ, Martus P, Runge M.
    J Musculoskelet Neuronal Interact; 2011 Mar; 11(1):34-45. PubMed ID: 21364273
    [Abstract] [Full Text] [Related]

  • 26. Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. FOSIT-Study-Group. Fosamax International Trial.
    Felsenberg D, Alenfeld F, Bock O, Hammermeister C, Gowan W.
    Maturitas; 1998 Nov 30; 31(1):35-44. PubMed ID: 10091203
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of monthly ibandronate in men with low bone density.
    Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G.
    Bone; 2010 Apr 30; 46(4):970-6. PubMed ID: 20060082
    [Abstract] [Full Text] [Related]

  • 28. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar 30; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 29. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling.
    Chesnut CH, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD.
    Am J Med; 1995 Aug 30; 99(2):144-52. PubMed ID: 7625419
    [Abstract] [Full Text] [Related]

  • 30. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.
    Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A.
    Arthritis Rheum; 2001 Jan 30; 44(1):202-11. PubMed ID: 11212161
    [Abstract] [Full Text] [Related]

  • 31. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH, Ensrud KE, Burdeska A, Mills T, Oral Ibandronate Study Group.
    J Bone Miner Res; 2004 Jan 30; 19(1):11-8. PubMed ID: 14753731
    [Abstract] [Full Text] [Related]

  • 32. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, Taves DH, Drost D.
    J Clin Endocrinol Metab; 1997 Feb 30; 82(2):620-8. PubMed ID: 9024265
    [Abstract] [Full Text] [Related]

  • 33. A double blind study of intranasal calcitonin for established postmenopausal osteoporosis.
    Kapetanos G, Symeonides PP, Dimitriou C, Karakatsanis K, Potoupnis M.
    Acta Orthop Scand Suppl; 1997 Oct 30; 275():108-11. PubMed ID: 9385282
    [Abstract] [Full Text] [Related]

  • 34. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, Bianchi G.
    Nephrol Dial Transplant; 2009 May 30; 24(5):1472-7. PubMed ID: 19075192
    [Abstract] [Full Text] [Related]

  • 35. A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D.
    Henriksen K, Byrjalsen I, Andersen JR, Bihlet AR, Russo LA, Alexandersen P, Valter I, Qvist P, Lau E, Riis BJ, Christiansen C, Karsdal MA, SMC021 investigators.
    Bone; 2016 Oct 30; 91():122-9. PubMed ID: 27462009
    [Abstract] [Full Text] [Related]

  • 36. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.
    Ellerington MC, Hillard TC, Whitcroft SI, Marsh MS, Lees B, Banks LM, Whitehead MI, Stevenson JC.
    Calcif Tissue Int; 1996 Jul 30; 59(1):6-11. PubMed ID: 8661976
    [Abstract] [Full Text] [Related]

  • 37. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May 30; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

  • 38. Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate.
    Cosman F, Nieves JW, Zion M, Garrett P, Neubort S, Dempster D, Lindsay R.
    J Clin Endocrinol Metab; 2015 Jul 30; 100(7):2769-76. PubMed ID: 25961136
    [Abstract] [Full Text] [Related]

  • 39. Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis.
    Luckey M, Kagan R, Greenspan S, Bone H, Kiel RD, Simon J, Sackarowitz J, Palmisano J, Chen E, Petruschke RA, de Papp AE.
    Menopause; 2004 Jul 30; 11(4):405-15. PubMed ID: 15243278
    [Abstract] [Full Text] [Related]

  • 40. Comparison of different treatment modalities for postmenopausal patients with osteopenia: hormone replacement therapy, calcitonin and clodronate.
    Tiraş MB, Noyan V, Yildiz A, Biberoğlu K.
    Climacteric; 2000 Jun 30; 3(2):92-101. PubMed ID: 11910657
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.